Genmab

	22/4 09:10 af bibob	Også enig med kkjoel. Når plusset er der kan man se hvilke skribenter der er " nassere ". Ville være dejligt at se et plus ved hver skribent. ;-)
	22/4 09:03 af Parasitism	Enig Kkjoel :)
	22/4 09:01 af kkjoel	betalere -> donatører
	22/4 09:00 af kkjoel	Enig, smid dem bare væk. Men jeg vil da helst ligestilles med alle andre betalere, bare sådan rent principielt ;-)
	22/4 08:59 af Solsen	Hvad skal I bruge plusserne til. Det er spild af Helges tid efter min mening. Vi betaler gerne 10-20 tkr årligt for tv, aviser mv. Men slippe 100 kr til dette forum er svært for mange selv om vi kan tjene gode penge ved at være opdateret og finde nye investerings,uligheder her.
	22/4 08:59 af kkjoel	21.02
	22/4 08:55 af kkjoel	Er faktisk i samme situation som Parasitism, Helge - overførte i februar.
	22/4 08:38 af bibob	Rvd induction impresses in Myeloma, but 4-drug regimens mark the future. (link)
	22/4 08:12 af Parasitism	Helge - du fik aldrig givet mig mit plus tilbage :(
	22/4 08:12 af Parasitism	God morgen :-)
	22/4 07:25 af Helge Larsen/PI-redaktør	God morgen. :-)
	22/4 07:06 af Plimsoller	God morgen :-)
	21/4 17:07 af JKY_VH	enig bestemt godkendt.
	21/4 17:06 af gdn55	Det går jo endda.
	21/4 17:01 af JKY_VH	men vi faldt tilbage til et luk i 1585:-)
	21/4 16:38 af JKY_VH	vi er da ellers på vej til noget der kunne ligne et luk i dagens højeste
	21/4 16:37 af E L	sry not meant for here lol
	21/4 16:37 af E L	rumour
	21/4 14:14 af JKY_VH	Jo da Genmab er oppe med 1 kr. pt. i et surt marked
	21/4 13:58 af Smadsen128	Er der ingen kurser der opdateres iøjeblikket
	21/4 08:59 af E L	a summary of the recent blood article
	21/4 08:59 af E L	Results of the safety run-in phase of the ANDROMEDA trial in patients with newly diagnosed AL amyloidosis (link)
	21/4 06:55 af Solsen	Det er da om noget et V-recovery :-)
	21/4 00:21 af Helge Larsen/PI-redaktør	(link)

	20/4 17:25 af Solsen	Yes its crazy ;-)
	20/4 17:01 af GeorgeBest	NBI still very strong...
	20/4 16:15 af E L	topf empfehlung! No idea who the guy is, but as it is quiet here, just for fun, from minute 4. He can't really get the market cap right, but he thinks they can do something for Corona ;-) 'Ein heizer übernahmekandidat" ;-) (link)
	20/4 14:43 af Solsen	Yes if the patients cant se the benefit. We show them. Good to se from a investor view.
	20/4 14:40 af E L	because they say 'transitioning from...' instead of 'relapsing from....' , right? actively looking to switch patients into ofa strategy it seems
	20/4 14:34 af Solsen	Aggressiv approach EL :-)
	20/4 14:02 af E L	Novartis starting a new "An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab (ARTIOS)" (link)
	20/4 09:28 af Solsen	Der bliver kamp til stregen og Novartis skal stå tidligt op for at presse Roche af banen.
	20/4 09:25 af Solsen	Roche kører sideløbende med udvikling af Ocrevus til sc version med HALOs ENHANZE teknologi.
	20/4 08:54 af bibob	Ja, snart tid til st få Ofa på banen.
	20/4 08:47 af GeorgeBest	US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time (link)
	20/4 07:19 af transalp	Go morgen frostklar flot morgen .. :)
	19/4 10:01 af E L	(link)
	19/4 10:01 af E L	(link) Evolving role of Daratumumab: From backbencher to a frontline agent https://sci-hub.tw/(link)
	19/4 07:04 af GeorgeBest	Amyloidosis: Safety Run-in trial of Phase 3 Dara-CYBORDE trial showed 82% >VGPR with high renal organ response rate (link)
	19/4 06:30 af transalp	Go morgen.. :)
	18/4 18:20 af GeorgeBest	Link til Twitter, virker hos mig.
	18/4 17:21 af GeorgeBest	Dara i leukemi (link)
	18/4 16:25 af StockBull	Genmab tilbage i kanalen (link)
	18/4 11:18 af StockBull	(link)
	18/4 11:18 af StockBull	These sorts of numbers are larger than would be required by clinical trials, so suggest that Gilead is ramping up production for clinical use. The firm also said it was hoping to increase output again as raw materials became available. Looking further ahead, at even broader use, the firm has set an “ambitious goal” of producing more than 500,000 treatment courses by October, and 1m by the end of the year, from a geographically diverse group of suppliers.
	18/4 11:17 af StockBull	Even if the drug proves successful, it is still experimental, and only limited quantities of such drugs are usually available. Gilead has increased production to meet demand for use in trials. On April 5th, it said it had enough to supply more than 140,000 patients.
	18/4 11:16 af StockBull	any conclusions was "premature and scientifically unsound".
	18/4 11:15 af StockBull	For all the excitement it generated, the STAT report was little more than a leaked conversation between doctors. It revolved around a trial at the University of Chicago with 125 patients, mostly severely ill with covid-19. One of the doctors is reported as saying that most of the patients had been discharged and only two had died. But even if this is correct, the lack of a placebo group makes it hard to assess the real worth of the drug. The University of Chicago itself warned that drawing any
	18/4 11:13 af StockBull	However the study has proven divisive among scientists. To begin with, errors can be large given the small number of patients. Moreover, the trial was not “randomised”, so there is no way of knowing whether the sample properly reflects the population of severely afflicted patients. Last, there was no comparison group that was given a placebo, ie, a substance with no therapeutic effect, to establish the real effectiveness of the drug.
	18/4 11:13 af StockBull	Remdesivir: science remains equivocal about whether this drug actually works for covid-19 sufferers. Two trials in China have already failed, because of lack of enrolment. (China started its trials relatively late in its epidemic, so it was hard to recruit sufficient numbers of patients.) The recent publication in the New England Journal of Medicine, of a study of remdesivir given to 53 severely afflicted patients, reported that 68% of them improved.